Director’s Bold Stock Sale Shakes Up Surgery Partners!

New insider activity at Surgery Partners ( (SGRY) ) has taken place on August 15, 2025.

Director Teresa DeLuca has made a significant move by selling 20,018 shares of Surgery Partners stock, amounting to a total transaction value of $455,209.

Recent Updates on SGRY stock

Surgery Partners has recently experienced significant developments impacting its stock performance. The company announced a substantial refinancing effort through a second amendment to its credit agreement, introducing new term loans to enhance financial flexibility. Despite reporting strong revenue and EBITDA growth in its Q2 earnings, the company faced a net loss, attributed to increased interest expenses and slower M&A activity. The resignation of Wayne S. DeVeydt as Executive Chairman and the appointment of Blair E. Hendrix as Chairman mark a notable leadership change. Analysts have maintained a positive outlook on the stock, citing strong operational performance and strategic growth initiatives, although concerns about profitability, high leverage, and potential regulatory impacts remain. The company’s focus on strategic expansions, physician recruitment, and portfolio optimization is expected to drive future growth, despite the challenges.

Spark’s Take on SGRY Stock

According to Spark, TipRanks’ AI Analyst, SGRY is a Neutral.

Surgery Partners’ overall stock score reflects strong revenue growth and strategic expansion efforts, which are tempered by profitability challenges and high leverage. Technical indicators suggest moderate bullish momentum, while recent corporate events and earnings call insights provide a balanced outlook. The negative P/E ratio and lack of dividend yield weigh on the valuation score.

To see Spark’s full report on SGRY stock, click here.

More about Surgery Partners

YTD Price Performance: 5.68%

Average Trading Volume: 1,725,371

Technical Sentiment Signal: Sell

Current Market Cap: $2.88B